RimonabantReport
 
Your INDEPENDENT source of news and reviews about the new diet drug rimonabant
 
This news site is NOT affiliated with NOR endorsed by Sanofi-Aventis, which markets rimonabant as Acomplia®
 
 
Get Free Email Alerts to News About Rimonabant
 

Thank you for visiting the Rimonabant Report, your most comprehensive source of news and reviews about the new diet drug.

We hope you will check back with us frequently for the latest news and information about this promising new drug.

But in response to many requests, we now are offering an email alert service that will let you know when there is breaking news about rimonabant.

If you would like to take advantage of this service, please simply register below.

Last Name, First Name:


City & State (or Country):


E-mail Address:


Any comments you may have about Rimonabant Report.


Thank you for filling out our email alert signup form.

While we may contact you from time to time to alert you to important information about rimonabant or other special Medical Week news, WE PROMISE YOU your registration information will NEVER be used outside of our company.

 

Copyright © 2004-2007 Medical Week News, Inc. All Rights Reserved.

 
Other Diet Resources
Privacy Policy | Terms and Disclaimers | About the Rimonabant Report
Contact Us
Click to VerifyWe subscribe to the HONcode principles of the HON Foundation.

This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Aventis which markets it in Europe as Acomplia. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition. .

(c) 2004-2007 Medical Week News, Inc. All Rights Reserved

Last Updated: 03/05/2008